AmbioPharm

About the company

Unclaimed editorial profile · compiled from public sources.

AmbioPharm is a contract development and manufacturing organization focused on custom peptide active pharmaceutical ingredients for pharmaceutical and biotech clients. Its website lists GMP manufacturing by solution-phase, solid-phase or hybrid synthesis, as well as non-GMP process development, analytical method development and validation, vaccine peptides and cosmetic peptides. According to CordenPharma's May 2026 announcement, AmbioPharm has sites in North Augusta, South Carolina, and Shanghai, China. A banner on its website says the company has been acquired by CordenPharma. The company says it is expanding commercial-scale peptide API production in South Carolina.

Products & services

The company publicly describes the following offerings. Availability and suitability must be confirmed directly.

• Custom peptide API manufacturing
• Solution-phase, solid-phase and hybrid peptide synthesis
• Process development
• Analytical method development and validation
• Peptide vaccine ingredients
• Cosmetic peptide manufacturing
• Custom organic synthesis

What the company says

These are the company’s own statements, not confirmed by Vetted Vial.

• Says it is FDA-inspected
• Says it has one of the largest peptide manufacturing capacities in the world
• Says it is investing $121.9 million to add commercial-scale peptide API production in North Augusta by 2027

Public records

May 27, 2026: CordenPharma announced an agreement to acquire AmbioPharm.

Source and review scope

Public website checked October 23, 2026. Profile compiled by Vetted Vial from public sources; not supplied or endorsed by the company. Location stated by the company: North Augusta, South Carolina, USA; Shanghai, China. Official source.

Confirm current products, services, terms, and documentation directly with the company.